Answers are grounded in this paper and cite their sources.
The rise in serum calcitonin (delta-CT240 min) has been measured during hypercalcemia induced by i.v. infusion of calcium gluconate. This calcium infusion test was used in a prospective screening for medullary carcinoma of the thyroid (MCT) in 4 families with Sipple's syndrome as well as in 3 sporadic cases of MCT. In 16 normal controls delta-CT240 was minus 0.2-+ 0.5 ng/ml (mean plus or minus 2 S.D.). Delta-CT240 was normal in 2 patients with chronic hypocalcemia. In all 14 MCT patients delta-CT240 was markedly higher (min-max 2.2-630 ng/ml), i.e. no false negatives were found. However, in these cases, the diagnosis was already evident from basal serum calcitonin (S-CT), which up to now has been our most sensitive diagnostic technique for MCT. 19 first-degree relatives of patients with Sipple's syndrome presented no signs of MCT. In 14 of these delta-CT240 was normal ("healthy relatives"), but in 5 it was slightly elevated, intermediate between the controls and the MCT patients. These 5 borderline cases were more sharply delineated from normal by delta-CT240 than by S-CT. Thus our calcium infusion test seems to be the most sensitive method for early diagnosis of occult MCT. We recommend the calcium infusion test for: (a) screening for MCT in all Sipple relatives with normal or only slightly elevated basal S-CT, (b) postoperative control in both sporadic and hereditary MCT, (c) investigation of supposed non-MCT tumours with calcitonin production.
No takes yet. Share an insight, caveat, or question.
Telenius‐Berg et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: